Bright Minds Biosciences (DRUG) Competitors

+0.04 (+3.77%)
(As of 05/17/2024 ET)


Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Petros Pharmaceuticals (PTPI), China Pharma (CPHI), Lipella Pharmaceuticals (LIPO), Kazia Therapeutics (KZIA), ZyVersa Therapeutics (ZVSA), Seelos Therapeutics (SEEL), NexImmune (NEXI), GT Biopharma (GTBP), Tharimmune (THAR), and Exicure (XCUR). These companies are all part of the "pharmaceutical preparations" industry.

Bright Minds Biosciences vs.

Bright Minds Biosciences (NASDAQ:DRUG) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Petros Pharmaceuticals received 1 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.

Bright Minds BiosciencesN/AN/A
Petros PharmaceuticalsOutperform Votes
Underperform Votes
No Votes

Bright Minds Biosciences has higher earnings, but lower revenue than Petros Pharmaceuticals. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bright Minds BiosciencesN/AN/A-$5.47M-$1.01-1.09
Petros Pharmaceuticals$5.82M0.70-$8.16M-$7.37-0.08

In the previous week, Petros Pharmaceuticals had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Petros Pharmaceuticals and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.32 beat Petros Pharmaceuticals' score of -0.69 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Bright Minds Biosciences Positive
Petros Pharmaceuticals Negative

Bright Minds Biosciences has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.

Bright Minds Biosciences has a net margin of 0.00% compared to Petros Pharmaceuticals' net margin of -181.87%. Bright Minds Biosciences' return on equity of -77.40% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bright Minds BiosciencesN/A -77.40% -70.90%
Petros Pharmaceuticals -181.87%-102.32%-32.41%

Petros Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 582.59%. Given Petros Pharmaceuticals' higher possible upside, analysts clearly believe Petros Pharmaceuticals is more favorable than Bright Minds Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Minds Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)


Petros Pharmaceuticals beats Bright Minds Biosciences on 8 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRUG vs. The Competition

MetricBright Minds BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.87M$6.73B$5.30B$7.96B
Dividend YieldN/A2.61%43.94%3.91%
P/E Ratio-1.0922.40154.7018.77
Price / SalesN/A251.762,362.9377.92
Price / CashN/A36.3936.6031.98
Price / Book0.855.895.754.76
Net Income-$5.47M$130.47M$106.86M$217.17M
7 Day Performance3.76%1.50%1.41%2.90%
1 Month Performance-6.78%3.75%4.29%6.57%
1 Year Performance-57.85%-1.19%7.61%10.17%

Bright Minds Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Petros Pharmaceuticals
2.155 of 5 stars
-87.0%$4.71M$5.82M-0.1121Earnings Report
Upcoming Earnings
News Coverage
China Pharma
0 of 5 stars
N/A-80.4%$4.67M$7.01M0.00231Earnings Report
Analyst Forecast
News Coverage
Gap Down
Lipella Pharmaceuticals
3.4138 of 5 stars
-60.9%$4.64M$449,617.000.005Upcoming Earnings
Gap Up
Kazia Therapeutics
0 of 5 stars
N/A-78.0%$4.82M$20,000.000.002,021Gap Down
ZyVersa Therapeutics
2.329 of 5 stars
-96.6%$4.86MN/A0.007News Coverage
Gap Down
Seelos Therapeutics
1.7896 of 5 stars
-99.2%$4.89M$2.20M0.0015Upcoming Earnings
Stock Split
News Coverage
Gap Up
0 of 5 stars
N/A-55.5%$4.92MN/A-0.1222Upcoming Earnings
Positive News
Gap Up
GT Biopharma
1.8704 of 5 stars
-63.2%$4.46MN/A-0.362Upcoming Earnings
News Coverage
0 of 5 stars
N/AN/A$4.35MN/A-0.022Positive News
3.1568 of 5 stars
N/A-51.9%$4.33M$28.83M0.307News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:DRUG) was last updated on 5/18/2024 by Staff

From Our Partners